Cixutumumab
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tumors
Conditions
Tumors
Trial Timeline
Nov 1, 2009 โ Apr 1, 2015
NCT ID
NCT01007032About Cixutumumab
Cixutumumab is a phase 1 stage product being developed by Eli Lilly for Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT01007032. Target conditions include Tumors.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01007032 | Phase 1 | Completed |
Competing Products
20 competing products in Tumors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E7050 | Eisai | Phase 1 | 33 |
| SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent) | Syros Pharmaceuticals | Phase 1 | 25 |
| [203Pb]VMT-ฮฑ-NET + [212Pb]VMT-ฮฑ-NET | Perspective Therapeutics | Phase 1/2 | 33 |
| [212Pb] VMT-ฮฑ-NET | Perspective Therapeutics | Phase 1 | 25 |
| ZN-c3 + Bevacizumab + Pembrolizumab | Zentalis Pharmaceuticals | Phase 1 | 25 |
| IMC-18F1 | Eli Lilly | Phase 1 | 33 |
| OKI-179 | OnKure Therapeutics | Phase 1 | 25 |
| ACR-2316 | Acrivon Therapeutics | Phase 1 | 25 |
| LY2875358 + Erlotinib + Gefitinib | Eli Lilly | Phase 1 | 33 |
| Tomivosertib (eFT-508) | eFFECTOR Therapeutics | Phase 2 | 44 |
| SPYK04 | Chugai Pharmaceutical | Phase 1 | 33 |
| AUBE00 + Cetuximab | Chugai Pharmaceutical | Phase 1 | 33 |
| LUNA18 + Cetuximab | Chugai Pharmaceutical | Phase 1 | 33 |
| ERY974 | Chugai Pharmaceutical | Phase 1 | 33 |
| DS3610a | Daiichi Sankyo | Phase 1 | 33 |
| Tivantinib (ARQ 197) Capsule + Tivantinib (ARQ 197) Tablet + Tivantinib (ARQ 197) Capsule D, oral | Daiichi Sankyo | Phase 1 | 33 |
| DS-1123 | Daiichi Sankyo | Phase 1 | 33 |
| DS-8201a | Daiichi Sankyo | Phase 2 | 52 |
| DS-5573a | Daiichi Sankyo | Phase 1 | 33 |
| DS-8201a (DP1) + DS-8201a (DP2) + DS-8201a (DP) | Daiichi Sankyo | Phase 1 | 33 |